By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Investment firm Oppenheimer revised its revenue estimates for Life Technologies while maintaining its "Outperform" rating, amid concerns about the effect of the Japanese earthquake, competition in the next-generation sequencing space, and government funding on the company's business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

At her blog, Sally Rockey dives into National Institutes of Health funding data.